Last updated: May 31, 2026
Suppliers for Clindamycin Phosphate in 0.9% Sodium Chloride (IV): Who Makes the Infusion and What to Source
Clindamycin phosphate in 0.9% sodium chloride is an intravenous (IV) admixture product used for infusion. Supplier availability depends on whether you are sourcing (1) a finished drug product/ready-to-infuse solution from an NDA/ANDA manufacturer or (2) a contract manufacturing organization (CMO) or hospital/FDL compounding supply chain for admixture preparation.
What companies supply “clindamycin phosphate in 0.9% sodium chloride” IV infusion products?
Direct finished-product suppliers vary by market, concentration, and package configuration (single-dose bags, pharmacy bulk vials, or unit-dose systems). In practice, supply typically comes from one of two channels:
- Finished sterile infusions manufactured under FDA-approved marketing authorizations (NDA/ANDA) and distributed as ready-to-administer bags.
- Raw sterile clindamycin phosphate plus sterile 0.9% sodium chloride sourced by hospitals, group purchasing organizations, or specialty wholesalers, then compounded in pharmacy using sterile compounding standards.
Supplier identification requires matching the exact NDC/bag size/concentration and whether it is pharmacy compounded or commercially manufactured. Without that, the supplier universe cannot be stated accurately.
Which concentrations and bag sizes affect supplier lists?
Supplier lists change when any of these differ:
- Clindamycin concentration (mg/mL)
- Total volume per bag (e.g., 50 mL, 100 mL)
- Bag container material (plastic bag type)
- Strength of clindamycin phosphate salt form
- Labeling format (premix ready-to-infuse vs components for admixture)
Is clindamycin phosphate in 0.9% sodium chloride sold as a premix or only compounded from vials?
Both models exist, but procurement routing differs:
Commercial premix (ready-to-infuse)
- Distributed as a sterile infusion bag.
- Procured through standard wholesaler distribution under an NDC tied to a marketing authorization.
- Requires sourcing based on NDC, DEA schedule status (if applicable; clindamycin is not typically controlled), and labeled stability/storage.
Pharmacy admixture (components compounded)
- Hospitals and 503B/503A compounding pharmacies combine:
- sterile clindamycin phosphate concentrate, and
- sterile 0.9% sodium chloride infusion fluid.
- Procurement is split across:
- clindamycin phosphate injectable supplies (often vials),
- normal saline sterile bags or bottles,
- sterile compounding capacity.
What is the best way to source clindamycin phosphate + 0.9% sodium chloride for IV use?
High-reliability procurement usually follows two steps:
- Source by NDC for premix products if your facility requires ready-to-administer bags.
- Source component vials and saline bags if pharmacy admixture is standard or if premix supply is constrained.
Procurement controls that determine which suppliers can meet needs:
- sterile manufacturing site approvals
- U.S. distribution footprint
- lot traceability
- expiration dating and distribution lead times
- compatibility documentation for admixtures
- ability to support surge demand
Which supplier types are relevant: finished drug manufacturers, sterile CMOs, or wholesalers?
You typically engage one of these categories:
1) Finished sterile infusion manufacturers
- Provide ready-to-infuse bags.
- Your procurement depends on NDC availability and inventory.
2) 503B outsourcing facilities (sterile compounding)
- Compound clindamycin phosphate in normal saline for downstream distribution.
- Procurement depends on outsourcing formulary alignment and purchasing agreements.
3) Component manufacturers (vials + saline)
- Clindamycin phosphate injectable manufacturers plus normal saline suppliers.
- Procurement depends on your compounding SOP and BUD requirements.
4) Specialty wholesalers / GPO distributors
- Consolidate supply and may control allocation during shortages.
- Procurement depends on contracted NDCs and package sizes.
How do you qualify suppliers for IV clindamycin phosphate admixtures?
Qualification in sterile injectable supply chains usually requires:
- sterile cGMP manufacturing confirmation
- quality agreement terms covering:
- COA and stability data access,
- lot traceability and recalls,
- change control notifications,
- packaging and labeling compliance
- compatibility and infusion stability documentation for the specific admixture
- documentation for pharmacy admixture sites:
- sterile technique controls (ISO class/cleanroom controls for preparation),
- beyond-use dating policy, and
- batch record controls for compounded admixtures
When supply is constrained, what generic-equivalent or alternative sourcing options exist?
If premix supply tightens, facilities usually switch by policy to one of:
- component-based compounding (clindamycin phosphate injection + sterile saline)
- alternative premix volumes from the same manufacturer (if formulation is equivalent)
- alternate manufacturer NDCs for the premix
- outsourcing facility substitution where your formulary permits
This is operationally driven by:
- stock on hand and lead time for the next available lot
- storage constraints (refrigerated vs room temperature)
- infusion compatibility documentation accepted by your clinical team
Which logistics details determine “supplier fit” for procurement?
Key procurement constraints include:
- shipping temperature requirements
- carton and vial/bag count per case
- maximum permitted substitution under your pharmacy formulary
- adverse event reporting channel
- recall notification process
Key Takeaways
- “Clindamycin phosphate in 0.9% sodium chloride” sourcing depends on whether you need a premix ready-to-infuse bag or component-based admixture.
- Supplier lists change materially with NDC, concentration, and bag volume.
- Qualification hinges on sterile cGMP readiness, lot traceability, and compatibility/stability documentation for the exact admixture configuration.
FAQs
-
How do I find suppliers for clindamycin phosphate in 0.9% sodium chloride by NDC?
Match the exact NDC and bag size to distributor catalogs; premix suppliers are NDC-anchored.
-
What’s the difference between sourcing premix vs components for IV clindamycin?
Premix is NDC-based and ready to administer; components split sourcing across clindamycin vials and sterile saline with pharmacy/outsourcing compounding.
-
What drives lead time variability for IV antibiotic premix bags?
Concentration and bag volume, manufacturing allocation, wholesaler inventory, and distribution temperature requirements.
-
Can 503B facilities supply compounded clindamycin in normal saline?
Yes where authorized and where your formulary contracts permit; sourcing is through the 503B distributor channel rather than standard premix NDC purchase.
-
What quality documents should procurement require for IV admixture supplies?
COAs, lot traceability, recall/change control terms, and admixture stability or beyond-use dating support for your specific preparation workflow.
References
- U.S. Food and Drug Administration (FDA). Drug Shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
